newsOTX-2002, a programmable epigenetic medicine is the first mRNA therapy…
28 October 2022 | By Catherine Eckford (European Pharmaceutical Review)
OTX-2002, a programmable epigenetic medicine is the first mRNA therapy to target MYC dysregulation and could treat hepatocellular carcinoma.